Evidence map›Paper›PMID 29321424›Full record

ArticleInternal medicine (Tokyo, Japan)2018

Anti-MuSK Antibody-positive Myasthenia Gravis Successfully Treated with Outpatient Periodic Weekly Blood Purification Therapy.

Kentaro Deguchi, Kosuke Matsuzono, Yumiko Nakano, Syoichiro Kono, Kota Sato, Shoko Deguchi, Katsuyuki Tanabe, Nozomi Hishikawa, Yasuyuki Ota, Toru Yamashita and 3 more

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
  3. Muscle-Specific Kinase Myasthenia Gravis.Frontiers in immunology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 1 country.

Kentaro DeguchiDepartment of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Kosuke MatsuzonoDepartment of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Yumiko NakanoDepartment of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Syoichiro KonoDepartment of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Kota SatoDepartment of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Shoko DeguchiDepartment of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Katsuyuki TanabeDepartment of Nephrology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Nozomi HishikawaDepartment of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Yasuyuki OtaDepartment of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Toru YamashitaDepartment of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Kiyoe OhtaClinical Research Center, National Hospital Organization Utano National Hospital, Japan.
Masakatsu MotomuraDepartment of Neurology and Strokology, Nagasaki University Hospital, Japan.
Koji AbeDepartment of Neurology, Graduate School of Medicine and Dentistry, Okayama University, Japan.
Okayama University · JPNagasaki University Hospital · JPUtano Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 37-year-old man with anti-muscle-specific tyrosine kinase (MuSK) antibody-positive myasthenia gravis (MG) presented with subacute progressive dysphagia and muscle weakness of the neck and bilateral upper extremities. Conventional immune-suppressive treatments and high-dose intravenous immunoglobulin were ineffective. He then displayed repeated exacerbations and remissions over the course of two years, despite two to four sessions of plasma exchange (PE) every two months. The patient was successfully treated with outpatient periodic weekly blood purification therapy with alternative PE and double-filtration plasmapheresis using an internal shunt. This case report suggests the benefits of blood purification therapy with an internal shunt against anti-MuSK antibody-positive MG.

Indexed as

Ambulatory CarePlasma ExchangePlasmapheresisAdultAutoantibodiesDeglutition DisordersHumansImmunoglobulins, IntravenousMaleMuscle WeaknessMyasthenia GravisReceptor Protein-Tyrosine KinasesReceptors, CholinergicTyrosineAutoantibodiesImmunoglobulins, IntravenousMUSK protein, humanReceptor Protein-Tyrosine KinasesReceptors, CholinergicTyrosineanti-MuSK antibodiesmyasthenia gravisperiodic weekly blood purification therapy

Identifiers

PMID29321424
PMCPMC5995714
OpenAlexW2783617717

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.